[email protected]/(408) 457-3700

About Vestan, Inc.

Histopathology of sentinel lymph nodes (SLN) during breast cancer and melanoma surgery is a critical determinant of the patient's post surgical care. Vestan's drug/device combination product for SLN visualization has significant safety and visualization advantages over the current standard of care. It has completed a successful Phase 2 study in melanoma patients and is in Phase 2 testing in breast cancer patients

You need to register as an accredited investor before we can show you the details of any investment opportunities.

VentureHealth is currently invite only.

Request An Invite!

Startup's Info

Location:
Salt Lake City
Markets:
Pharmaceuticals
Therapeutic Areas:
Oncology